Abstract
In traditional pure protein high-throughput drug screens, also called in vitro screens, individual compounds from a small molecule collection are tested to determine whether they inhibit the enzymatic activity or binding properties of a purified target protein. In contrast, phenotypic high-throughput drug screens, also called chemical genetic or in vivo screens, investigate the ability of individual compounds from a collection to inhibit a biological process or disease model in live cells or intact organisms. In this review, the role of phenotypic screening techniques to identify novel therapeutic agents for the treatment of cardiovascular disease will be discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 207-212 |
| Number of pages | 6 |
| Journal | Trends in Cardiovascular Medicine |
| Volume | 19 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1 Aug 2009 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'The Application of Phenotypic High-Throughput Screening Techniques to Cardiovascular Research'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver